Medicare Enrolled
Dr. Basharath Khan, MD
Hematology & Oncology · Rolling Meadows, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khan
Dr. Basharath Khan is a hematology & oncology specialist in Rolling Meadows, IL, with 16 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 22,872 Medicare services across 1,441 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khan received a total of $3,906 from 49 pharmaceutical and/or device companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 29% volume in IL
$3,906 industry payments
Medicare Practice Summary
Medicare Utilization ↗22,872
Medicare services
Top 29% in IL for hematology & oncology
1,441
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,430 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,850 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 3,108 | $0 | $20 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,896 | $0 | $10 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
984 | $11 | $230 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
552 | $67 | $125 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
502 | $13 | $180 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
494 | $8 | $55 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
355 | $23 | $400 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
343 | $24 | $250 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
312 | $108 | $600 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
269 | $101 | $285 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
249 | $1 | $50 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
240 | $110 | $250 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
232 | $1 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
197 | $68 | $225 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
192 | $1 | $25 |
| Lactated Ringer's infusion, up to 1000 cc Intravenous administration of Lactated Ringer's solution, a fluid used to replace fluids and electrolytes, in amounts up to 1000 cubic centimeters. |
188 | $2 | $10 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
159 | $16 | $150 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
132 | $22 | $150 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
111 | $12 | $85 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
107 | $17 | $230 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
105 | $54 | $280 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
63 | $26 | $250 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
55 | $145 | $350 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
54 | $27 | $50 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
54 | $2 | $25 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
29 | $146 | $290 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
25 | $59 | $125 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $133 | $400 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.7% high complexity
78.9% medium
14.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,906
Total received (2018-2024)
Avg $558/year across 7 years
Top 47% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
201
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,881 (99.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$26 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,118
2023
$954
2022
$405
2021
$748
2020
$393
2019
$232
2018
$56
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$183
ABBVIE INC.
$137
PFIZER INC.
$101
GlaxoSmithKline, LLC.
$77
AstraZeneca Pharmaceuticals LP
$70
Merck Sharp & Dohme LLC
$70
Celgene Corporation
$61
JAZZ PHARMACEUTICALS INC.
$60
Daiichi Sankyo Inc.
$52
Janssen Biotech, Inc.
$47
Dexcom, Inc.
$46
Astellas Pharma US Inc
$43
Aveo Pharmaceuticals, Inc.
$42
Tempus AI, Inc
$25
SERVIER PHARMACEUTICALS LLC
$23
Gilead Sciences, Inc.
$21
TerSera Therapeutics LLC
$16
BeiGene USA, Inc.
$15
EMD Serono, Inc.
$14
E.R. Squibb & Sons, L.L.C.
$14
Top 3 companies account for 37.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$507
Merck Sharp & Dohme LLC
$314
Merck Sharp & Dohme Corporation
$253
Celgene Corporation
$216
AstraZeneca Pharmaceuticals LP
$178
PFIZER INC.
$170
Amgen Inc.
$159
Seagen Inc.
$149
ABBVIE INC.
$137
GlaxoSmithKline, LLC.
$132
Takeda Pharmaceuticals U.S.A., Inc.
$112
Regeneron Healthcare Solutions, Inc.
$96
E.R. Squibb & Sons, L.L.C.
$90
Janssen Biotech, Inc.
$82
Gilead Sciences, Inc.
$81
Exelixis Inc.
$80
SERVIER PHARMACEUTICALS LLC
$66
Genentech USA, Inc.
$66
EMD Serono, Inc.
$63
TerSera Therapeutics LLC
$63
JAZZ PHARMACEUTICALS INC.
$60
Astellas Pharma US Inc
$60
Daiichi Sankyo Inc.
$52
Coherus Biosciences Inc.
$49
ARRAY BIOPHARMA INC
$49
Dexcom, Inc.
$46
Janssen Pharmaceuticals, Inc
$46
Agios Pharmaceuticals, Inc.
$44
Aveo Pharmaceuticals, Inc.
$42
Stemline Therapeutics Inc.
$41
Lilly USA, LLC
$38
Incyte Corporation
$36
MorphoSys, US Inc.
$33
Mirati Therapeutics, Inc.
$31
Tempus AI, Inc
$25
Servier Pharmaceuticals LLC
$25
Eisai Inc.
$23
GENZYME CORPORATION
$23
Pharmacyclics LLC, an AbbVie Company
$22
AbbVie Inc.
$22
Deciphera Pharmaceuticals Inc.
$19
Fresenius Kabi USA, LLC
$18
Myriad Genetic Laboratories, Inc.
$16
Pharmacosmos Therapeutics Inc.
$15
Blueprint Medicines Corporation
$15
BeiGene USA, Inc.
$15
Pharmacyclics LLC, An AbbVie Company
$13
AMAG Pharmaceuticals, Inc.
$13
Secura Bio, Inc.
$2
Top 3 companies account for 27.5% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · BAVENCIO · BRUKINSA · CABLIVI · CYRAMZA · Cabometyx · DARZALEX · Dexcom G6 Transmitter · ELAHERE · ELIQUIS · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · FERAHEME · FOTIVDA · Fabhalta · Farydak · GAVRETO · GAZYVA · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYRISK · Monoferric · NINLARO · Nplate · OPDUALAG · Orserdu · PADCEV · PIQRAY · PROMACTA · Padcev · Pomalyst · QINLOCK · REBLOZYL · SANDOSTATIN · Stimufend · TASIGNA · TECVAYLI · TIBSOVO · TUKYSA · Tibsovo · Trodelvy · Udenyca · VENCLEXTA · VYXEOS · Vanflyta · XALKORI · XARELTO · XGEVA · XTANDI · Xermelo · ZEJULA · ZEPZELCA · Zoladex · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
274
Per 100K population
5.3
County median income
$81,797
Nearest hospital
NORTHWEST COMMUNITY HOSPITAL 1
1.9 mi
1.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khan is a mixed practice specialist, with above-average Medicare volume (top 29% in IL), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khan experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Khan performed 11,850 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $3,906 from 49 companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other hematology & oncology specialists in Rolling Meadows?
Dr. Khan's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Rolling Meadows
Browse hematology & oncology specialists in Rolling Meadows ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology